Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort

Cancer Communications(2025)10.1002/cac2.70020Source: DataRank Database

A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort is a research paper published in Cancer Communications (2025). On theSindex it has a DataRank of 0. It has been cited 3 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access3 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (11 grants)Impact (FWCI 1.53)OA: goldTopics (56)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (17)

Megan Othus ORCID,Sandip Pravin Patel ORCID,Raid Aljumaily,Khine Z. Win,Tanya Pejovic

Live enrichment

PubMed:40402690 PMC:PMC12365539 OpenAlex:https://openalex.org/W4410614995

National Cancer Institute

Grant: U10CA180888

National Cancer Institute

Grant: U10CA180819

National Cancer Institute

Grant: UG1CA233320

National Cancer Institute

Grant: UG1CA233193

National Cancer Institute

Grant: UG1CA233198

National Cancer Institute

Grant: UG1CA233340

National Institutes of Health

Bristol Myers Squibb Company

NIH HHS

Bristol Myers Squibb Company

NIH HHS

FWCI

1.53

Citation Percentile

0.8%

Citation Trend

2026

goldLicense: cc-by-nc-nd

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cac2.70020

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cac2.70020

publisherhttps://spj.science.org/doi/pdf/10.1002/cac2.70020

journalhttps://doi.org/10.1002/cac2.70020

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40402690

Fields of Study

Cancer Immunotherapy and BiomarkersLung Cancer Research StudiesChromatin Remodeling and CancerHumansFemaleCTLA-4 AntigenOvarian NeoplasmsNivolumabMiddle AgedProgrammed Cell Death 1 ReceptorIpilimumabHypercalcemiaCarcinoma, Small CellAdultImmune Checkpoint InhibitorsAgedAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesRare DiseasesDisease Progression

MeSH Terms

IpilimumabNivolumabImmune Checkpoint InhibitorsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansHypercalcemiaMiddle AgedOvarian NeoplasmsProspective StudiesCarcinoma, Small CellDisease ProgressionRare DiseasesCTLA-4 AntigenProgrammed Cell Death 1 Receptor

Keywords

IpilimumabNivolumabMedicineResponse Evaluation Criteria in Solid TumorsClinical endpointInternal medicineOncologyProgressive diseasePhases of clinical researchClinical trialImmune checkpointCancerImmunotherapyGastroenterologyChemotherapyRare TumorsDartSmall Cell Carcinoma Of The Ovary Hypercalcemic TypeS1609

Sustainable Development Goals

SDG 0: Good health and well-being